Goldman Sachs Group Inc Apellis Pharmaceuticals, Inc. Call Options Transaction History

Goldman Sachs Group Inc

  • $605 Billion
  • Q3 2024

Call Options

4 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q3 2023

May 14, 2024
BUY
$23.65 - $89.22 $473,000 - $1.78 Million
20,000 New
20,000 $760,000
Q3 2023

Nov 14, 2023
SELL
$23.65 - $89.22 $80,410 - $303,348
-3,400 Reduced 14.53%
20,000 $760,000
Q2 2023

May 14, 2024
BUY
$76.68 - $93.31 $1.79 Million - $2.18 Million
23,400 New
23,400 $2.13 Million
Q2 2023

Aug 14, 2023
BUY
$76.68 - $93.31 $1.79 Million - $2.18 Million
23,400 New
23,400 $2.13 Million

Others Institutions Holding APLS

# of Institutions
308
Shares Held
115M
Call Options Held
3.85M
Put Options Held
1.09M
View Full List

About Apellis Pharmaceuticals, Inc.

APLS Quotes by TradingView
  • Ticker APLS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 109,865,000
  • Market Cap $3.64B
  • Description
  • Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...
More about APLS
Track This Portfolio

Track Goldman Sachs Group Inc Portfolio

Follow Goldman Sachs Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Goldman Sachs Group Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email